National Laboratory of Virology, University of Pécs, Pecs, Hungary.
Institute of Biology, Faculty of Sciences, University of Pécs, Pecs, Hungary.
Geroscience. 2022 Jun;44(3):1263-1268. doi: 10.1007/s11357-022-00582-8. Epub 2022 May 11.
Since the appearance of coronavirus disease 2019 (COVID-19), numerous studies have been conducted to find effective therapeutics. Favipiravir (FVP) is one of the repurposed drugs which has been authorized in a few countries on an emergency basis to treat COVID-19. Elderly individuals especially 65 years or older are more prone to develop severe illness. We aim to provide a short summary of the current knowledge of the antiviral efficacy of favipiravir with respect to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected elderly patients. We found that it is rather controversial whether favipiravir is effective against SARS-CoV-2 infection. Data regarding patients 65 years or older is not sufficient to support or reject the usage of favipiravir for COVD-19 treatment. Further studies would be advisable to elicit the efficiency of favipiravir in elderly COVID-19 patients.
自 2019 年冠状病毒病（COVID-19）出现以来，已经进行了许多研究以寻找有效的治疗方法。法匹拉韦（FVP）是一种已被重新用于治疗 COVID-19 的药物，在一些国家已被紧急批准使用。老年人，尤其是 65 岁或以上的老年人更容易患上重病。我们旨在提供有关法匹拉韦对感染严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的老年患者的抗病毒疗效的现有知识的简短总结。我们发现，法匹拉韦是否对 SARS-CoV-2 感染有效存在争议。关于 65 岁及以上患者的数据不足以支持或拒绝使用法匹拉韦治疗 COVID-19。为了确定法匹拉韦在老年 COVID-19 患者中的疗效，还需要进一步的研究。
